Evaluation of the Efficacy of Lentiviral Vectors in Gene Therapy of ß-thalassemia Patients : A Systematic Review

Background: Beta thalassemia is a genetically blood abnormality identified through mutations which reduce the synthesis of the s-globin chain. Gene therapy through Lentiviral vectors have been cured many of genetically disorders. We aimed to assess the efficacy of lentiviral vector in treatment of s-thalassemia as a novel approach. Material and methods: In this systematic Review, studies have been collected from electronic databases: Web of Science, Scopus, and Medline (via PubMed) as International searched databases, search engine of Google Scholar were searched in Persian and English languages between 2012 and 2020. To preserve all valuable data was allocated and all articles were considered by two independent researchers. If there were abstracts of related articles, accessing full article the corresponding author was contacted. To find relevant articles in English language websites, keywords were selected according to MESH and included "thalassemia", "beta thalassemia", "β_thalassemia", "BTM", "lentvirus". Results: Finally, 20 articles that comprised including criteria were selected. Articles were quantitative (n=16), and qualitative (n=4) types and their year of publication varied from 2012 to 2020. Results showed that: the main outcome of the desire survey was therapeutic treatments for thalassemia worldwide. Gene therapy has emerged as a holistic and practical approach for the remaining 70% of non-competitors; while highly compatible donors for allogeneic bone marrow transplantation are accessible to less than 30% of all patients.Conclusion: nowadays, with the development of gene therapy, there is hope for a cure for genetic diseases. The successes of gene therapy techniques can bring laboratory methods of gene therapy a step closer to clinical and general use as a common treatment for genetic defects